Confirmation of safety of new gastrointestinal peptide Ghrelin in patients with chronic kidney disease

Confirmation of safety of new gastrointestinal peptide Ghrelin in patients with chronic kidney disease - Confirmation of safety of new gastrointestinal peptide Ghrelin in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021580

Enrollment

Registered

2016-03-23

Start date

2015-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Ghrelim 5microgram/kg body weight Ghrelim 10microgram/kg body weight Ghrelim 15microgram/kg body weight

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with chronic kidney disease eGFR less than 30ml but not on dialysis BMI less than 25 patients with well understanding of this study and submitting a written IC

Exclusion criteria

Exclusion criteria: patients with severe liver dysfunction patients with malignant neoplasm patients with severe infection patients with psycological problems patients who have allergy for wheat,milk and egg patients who plans for pregnancy who are judged to be inappropriate for the study by the attending physician

Design outcomes

Primary

Measure	Time frame
time course of ghrelin blood concentration	—

Secondary

Measure	Time frame
onset rate of any serious adverse events	—

Countries

Japan

Contacts

Public ContactShuu Wakino

School of Medicine Keio University Nephrology, Endocrinology and Metabolism

shuwakino@z8.keio.jp03-5363-3796

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026